Data / Drug companies / Unichem Pharmaceuticals (USA), Inc.
Unichem Pharmaceuticals (USA), Inc.: 178 products in the FDA NDC directory, labeler code 29300
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Unichem Pharmaceuticals (USA), Inc. (labeler code 29300) lists 178 products in the FDA National Drug Code Directory, covering 56 finished drugs by generic name. By type: 177 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 2, 2026.
The request: Watch Unichem Pharmaceuticals (USA), Inc. (FDA labeler code 29300): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 29300
- Products in commercial distribution
- 178
- Packages
- 487
- Finished drugs by generic name
- 56
- Prescription products
- 177
- Over the counter products
- 1
- Controlled substance products
- Schedule IV 7, Schedule V 12
- Flagged as original packager
- 164 of 164 products that carry the flag
- Started marketing in the last 12 months
- 12
- Earliest marketing start
- March 7, 2007
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 178 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 177 | 99.4% |
| Over the counter drugs | 1 | 0.6% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 78 | 43.8% |
| Tablet, film coated | 51 | 28.7% |
| Capsule | 20 | 11.2% |
| Tablet, extended release | 12 | 6.7% |
| Tablet, film coated, extended release | 5 | 2.8% |
| Tablet, orally disintegrating | 4 | 2.2% |
| Capsule, extended release | 3 | 1.7% |
| Tablet, delayed release | 3 | 1.7% |
| Tablet, chewable | 2 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Alprazolam | 29300-363 | Tablet | Generic drugs (ANDA) | November 2, 2026 |
| Alprazolam | 29300-362 | Tablet | Generic drugs (ANDA) | November 2, 2026 |
| Alprazolam | 29300-361 | Tablet | Generic drugs (ANDA) | November 2, 2026 |
| Alprazolam | 29300-360 | Tablet | Generic drugs (ANDA) | November 2, 2026 |
| Pregabalin | 29300-446 | Capsule | Generic drugs (ANDA) | August 3, 2026 |
| Pregabalin | 29300-445 | Capsule | Generic drugs (ANDA) | August 3, 2026 |
| Pregabalin | 29300-444 | Capsule | Generic drugs (ANDA) | August 3, 2026 |
| Pregabalin | 29300-443 | Capsule | Generic drugs (ANDA) | August 3, 2026 |
| Pregabalin | 29300-442 | Capsule | Generic drugs (ANDA) | August 3, 2026 |
| Pregabalin | 29300-441 | Capsule | Generic drugs (ANDA) | August 3, 2026 |
| Pregabalin | 29300-440 | Capsule | Generic drugs (ANDA) | August 3, 2026 |
| Pregabalin | 29300-439 | Capsule | Generic drugs (ANDA) | August 3, 2026 |
| Hydrochlorothiazide | 29300-485 | Tablet | Generic drugs (ANDA) | April 3, 2025 |
| Lacosamide | 29300-367 | Tablet, film coated | Generic drugs (ANDA) | December 1, 2024 |
| Lacosamide | 29300-366 | Tablet, film coated | Generic drugs (ANDA) | December 1, 2024 |
| Lacosamide | 29300-365 | Tablet, film coated | Generic drugs (ANDA) | December 1, 2024 |
| Lacosamide | 29300-364 | Tablet, film coated | Generic drugs (ANDA) | December 1, 2024 |
| Guanfacine | 29300-463 | Tablet, extended release | Generic drugs (ANDA) | November 19, 2024 |
| Guanfacine | 29300-462 | Tablet, extended release | Generic drugs (ANDA) | November 19, 2024 |
| Guanfacine | 29300-461 | Tablet, extended release | Generic drugs (ANDA) | November 19, 2024 |
| Guanfacine | 29300-460 | Tablet, extended release | Generic drugs (ANDA) | November 19, 2024 |
| Tolterodine tartrate | 29300-307 | Capsule, extended release | Generic drugs (ANDA) | October 1, 2024 |
| Tolterodine tartrate | 29300-306 | Capsule, extended release | Generic drugs (ANDA) | October 1, 2024 |
| Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride | 29300-313 | Tablet, film coated, extended release | Generic drugs (ANDA) | September 10, 2024 |
| Doxazosin Mesylate | 29300-354 | Tablet | Generic drugs (ANDA) | January 10, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.